Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab Biosimilar (Shandong New Time Pharmaceutical Co. Ltd.), 利妥昔单抗生物类似药(山东新时代药业有限公司), 重组抗CD20人鼠嵌合单克隆抗体(山东新时代药业) + [4] |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
CD20 positive Diffuse Large B-Cell Lymphoma | China | 17 Jun 2025 | |
CD20 positive Follicular Lymphoma | China | 17 Jun 2025 | |
Chronic lymphocytic leukaemia refractory | China | 17 Jun 2025 | |
Recurrent Chronic Lymphoid Leukemia | China | 17 Jun 2025 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse large B-cell lymphoma recurrent | Phase 2 | - | 01 Jan 2022 |